Patents Examined by Delia Ramirez
  • Patent number: 8329472
    Abstract: The object of the present invention is to provide a method for suppressing foam formation by identifying a gene involved in foam formation during culture of an acetic acid bacterium and reducing or deleting the function of a protein encoded by the gene, a method for more efficiently producing vinegar that contains a high concentration of acetic acid by using an acetic acid bacterium in which foam formation has been suppressed by the above method, and vinegar produced by the above production method. An acetic acid bacterium with suppressed foam formation was obtained by isolating a gene encoding a protein involved in foam formation during culture of an acetic acid bacterium, then by altering the gene by a modification to reduce or delete the function of a protein involved in foam formation. Further provided is a method for efficiently producing vinegar with higher concentration of acetic acid with the use of the acetic acid bacterium.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: December 11, 2012
    Assignee: Mizkan Group Corporation
    Inventor: Aya Iida
  • Patent number: 8318451
    Abstract: Pseudomonas saccharophila G4-forming amylase (PS4), and variants thereof, advantageously can be used in an enzyme-catalyzed high temperature liquefaction step to produce ethanol from starch, e.g., cornstarch. PS4 produces significant amounts of maltotrioses, which can be utilized by S. cerevisiae in a subsequent fermentation step to produce ethanol. This property of PS4 advantageously allows ethanol to be produced from liquefacted starch in the absence of a saccharification step. PS4 variants are provided that exhibit improved properties, such as thermostability and/or altered exo-specific and endo-specific amylase activity.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: November 27, 2012
    Assignee: Danisco US Inc.
    Inventors: Andrew Shaw, Regina Chin, Karsten M. Kragh
  • Patent number: 8304222
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Grant
    Filed: April 26, 2012
    Date of Patent: November 6, 2012
    Assignee: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga
  • Patent number: 8288102
    Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: February 27, 2010
    Date of Patent: October 16, 2012
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8278085
    Abstract: The invention provides human protein complexes with endonuclease activity, including tRNA splicing endonuclease activity and 3? end pre-mRNA endonuclease activity, and pre-ribosomal RNA cleavage activity. The invention also provides a splice variant of human Sen2, and human protein complexes comprising the variant. The invention provides human protein complexes with pre-ribosomal RNA cleavage activity. The invention also provides antibodies that immunospecifically bind to a complex described herein or a component thereof, and uses of such antibodies. The present invention also provides methods of preparing and purifying the complexes and uses of the complexes inter alia, in screening, diagnosis, and therapy.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: October 2, 2012
    Assignee: PTC Therapeutics, Inc.
    Inventors: Christopher R. Trotta, Sergey Paushkin
  • Patent number: 8273556
    Abstract: 4-(Indol-3-ylmethyl)-4-hydroxy-2-oxoglutarate, which is useful as an intermediate in the synthesis of monatin, may be synthesized from indole pyruvic acid and pyruvic acid (and/or oxaloacetic acid) by using a novel aldolase derived from the genus Pseudomonas, Erwinia, Flavobacterium, or Xanthomonas.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: September 25, 2012
    Assignee: Ajinomoto Co., Inc.
    Inventors: Masakazu Sugiyama, Kunihiko Watanabe, Shigeru Kawahara
  • Patent number: 8252573
    Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered properties relative to the parent alpha-amylase.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: August 28, 2012
    Assignee: Novozymes A/S
    Inventors: Allan Svendsen, Carsten Andersen, Thomas Thisted, Claus Von Der Osten
  • Patent number: 8247212
    Abstract: The present invention provides a method of circulating algae in growing containers using thermally-induced convection techniques. In particular, a method of growing algae by providing a thermal gradient in algae containing medium is disclosed.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: August 21, 2012
    Assignee: Greenfire Partners LLC
    Inventors: Mark P. Muir, Alan D. Eastman, Randy Balik
  • Patent number: 8247190
    Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: August 21, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Ronald T. Raines, Julie C. Mitchell, Thomas J. Rutkoski
  • Patent number: 8241889
    Abstract: Strains of Cryptococcus flavescens which are superior antagonists of F. graminearum for suppression and control of FHB in cereals, particularly in wheat and barley, are described. The strains are prothioconazole tolerant variants of previously described C. flavescens OH 182.9 (NRRL Y-30216). Moreover, these prothioconazole tolerant variants exhibit significantly increased efficacy against F. graminearum in comparison to the parent strain OH 182.9.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: August 14, 2012
    Assignees: The United States of America as represented by the Secretary of State, The Ohio State University Research Foundation
    Inventors: David A. Schisler, Michael J. Boehm
  • Patent number: 8232060
    Abstract: In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: July 31, 2012
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill
  • Patent number: 8216818
    Abstract: An object of the present invention is to provide a novel ketose 3-epimerase, a process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, and a process for producing a ketose by using the enzyme. The present invention solves the above objects by providing a ketose 3-epimerase which is obtainable from a microorganism of the genus Rhizobium, a process for producing the same, a DNA encoding the enzyme, a recombinant DNA and transformant comprising the DNA, and a process for converting D- or L-ketohexose into corresponding D- or L-ketohexose by epimerizing the hydroxyl group at the C-3 position of the D- or L-ketohexose; and D- or L-ketopentose into corresponding D- or L-ketopentose by epimerizing the hydroxyl group at the C-3 position of the D- or L-ketopentose; by using the enzyme.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: July 10, 2012
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Kazuhiko Maruta, Kozo Yamamoto, Tomoyuki Nishimoto, Hiroto Chaen, Tetsuya Nakada
  • Patent number: 8187858
    Abstract: The present invention relates to a process for producing a human-type glycoprotein having reduced glycosylation by genetically manipulating an enzyme involved in glycosylation using a Hansenula polymorpha system. In detail, the present invention relates to a process for producing a human-type glycoprotein by identifying a dolichyl-phosphate-mannose dependent ¥á-1,3-mannosyltransferase gene from H. polymorpha, constructing a H. polymorpha mutant strain producing a glycoprotein exhibiting reduced glycosylation by disrupting the identified gene, and subjecting the mutant strain to various genetic manipulations for the synthesis of human-type glycan.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 29, 2012
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Hyun Ah Kang, Jeong Seok Park, Moo Woong Kim, Eun Jung Kim, Hye Yun Moon, Doo Byoung Oh, Joo Hyung Heo, Sang Ki Rhee
  • Patent number: 8183016
    Abstract: A method for synthesizing aromatic amino acids according to one aspect of the present invention includes processes of: (a) of preparing a thermostable a Thermus thermophilus aspartate aminotransferase by culturing an E. coli BL21(DE3) cell transformed with a vector comprising a gene encoding the Thermus thermophilus aspartate aminotransferase; (b) contacting the thermostable Thermus thermophilus aspartate aminotransferase of (a) with an amino donor and an amino acceptor at a temperature range of 50-80° C. to obtain an aromatic amino acid; (c) precipitating the aromatic amino acid of (b); and (d) recovering the thermostable Thermus thermophilus aspartate aminotransferase.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: May 22, 2012
    Assignee: I-Shou University
    Inventors: Tzann-Shun Hwang, Wei-Chun Cheng, Hui-Chuan Fu, Szu-Pei Wu
  • Patent number: 8178335
    Abstract: Methods and compositions are provided that relate to obtaining a recombinant DNA and RNA cleaving nuclease. This involves the over-expression of a fusion protein between maltose-binding protein and a truncated nuclease in a soluble form in the cytoplasm of a host cell from which it can be readily extracted.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: May 15, 2012
    Assignee: New England Biolabs, Inc.
    Inventor: Pei-Chung Hsieh
  • Patent number: 8168383
    Abstract: Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant polypeptides, probes for detecting it, isolated mutant polypeptides, and reagents for detecting the fusion and truncated polypeptides.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: May 1, 2012
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Herbert Haack, Laura Sullivan, Ailan Guo, Anthony Possemato, Joan MacNeill, Ting-Lei Gu, Jian Yu
  • Patent number: 8163529
    Abstract: A nicking endonuclease is described which has an amino acid sequence with at least 70% identity to SEQ ID NO:6 and comprising a mutation at least one of an arginine or glutamic acid corresponding to position 507 and position 546 respectively in SEQ ID NO:6.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: April 24, 2012
    Assignee: New England Biolabs, Inc.
    Inventors: Shuang-Yong Xu, Zhenyu Zhu, Timothy Meixsell
  • Patent number: 8163514
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: April 24, 2012
    Assignee: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga
  • Patent number: 8148117
    Abstract: The present invention relates to microorganisms and processes for the efficient preparation of L-amino acids such as L-methionine. In particular, the present invention relates to microorganisms and processes in which the formation and/or accumulation of homolanthionine in the methionine pathway is reduced and/or prevented.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: April 3, 2012
    Assignee: Evonik Degussa GmbH
    Inventors: Oskar Zelder, Andrea Herold, Corinna Klopprogge, Hartwig Schröder, Stefan Haefner, Elmar Heinzle, Christoph Wittmann, Jens Kroemer, Janice G. Pero, R. Rogers Yocum, Thomas A. Patterson, Mark Williams, Theron Herman
  • Patent number: 8148098
    Abstract: Rationally-designed LAGLIDADG meganucleases and methods of making such meganucleases are provided. In addition, methods are provided for using the meganucleases to generate recombinant cells and organisms having a desired DNA sequence inserted into a limited number of loci within the genome, as well as methods of gene therapy, for treatment of pathogenic infections, and for in vitro applications in diagnostics and research.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: April 3, 2012
    Assignee: Duke University
    Inventors: James Jefferson Smith, Derek Jantz, Homme W. Hellinga